ID   IRAK3_HUMAN             Reviewed;         596 AA.
AC   Q9Y616;
DT   09-NOV-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1999, sequence version 1.
DT   05-OCT-2010, entry version 84.
DE   RecName: Full=Interleukin-1 receptor-associated kinase 3;
DE            Short=IRAK-3;
DE            EC=2.7.11.1;
DE   AltName: Full=IL-1 receptor-associated kinase M;
DE            Short=IRAK-M;
GN   Name=IRAK3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, COFACTOR, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Peripheral blood lymphocyte;
RX   MEDLINE=99315891; PubMed=10383454; DOI=10.1074/jbc.274.27.19403;
RA   Wesche H., Gao X., Li X., Kirschning C.J., Stark G.R., Cao Z.;
RT   "IRAK-M is a novel member of the Pelle/interleukin-1 receptor-
RT   associated kinase (IRAK) family.";
RL   J. Biol. Chem. 274:19403-19410(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   INVOLVEMENT IN ASRT5, AND VARIANTS LEU-22; ALA-111; MET-134; VAL-400
RP   AND GLN-429.
RX   PubMed=17503328; DOI=10.1086/518259;
RA   Balaci L., Spada M.C., Olla N., Sole G., Loddo L., Anedda F.,
RA   Naitza S., Zuncheddu M.A., Maschio A., Altea D., Uda M., Pilia S.,
RA   Sanna S., Masala M., Crisponi L., Fattori M., Devoto M.,
RA   Doratiotto S., Rassu S., Mereu S., Giua E., Cadeddu N.G., Atzeni R.,
RA   Pelosi U., Corrias A., Perra R., Torrazza P.L., Pirina P., Ginesu F.,
RA   Marcias S., Schintu M.G., Del Giacco G.S., Manconi P.E., Malerba G.,
RA   Bisognin A., Trabetti E., Boner A., Pescollderungg L., Pignatti P.F.,
RA   Schlessinger D., Cao A., Pilia G.;
RT   "IRAK-M is involved in the pathogenesis of early-onset persistent
RT   asthma.";
RL   Am. J. Hum. Genet. 80:1103-1114(2007).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-110; SER-154; SER-415;
RP   SER-467; SER-484; SER-510 AND SER-512, AND MASS SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [5]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-57; SER-84; ILE-147; VAL-171;
RP   LEU-288; GLN-384; THR-391 AND ASN-482.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Inhibits dissociation of IRAK1 and IRAK4 from the Toll-
CC       like receptor signaling complex by either inhibiting the
CC       phosphorylation of IRAK1 and IRAK4 or stabilizing the receptor
CC       complex (By similarity).
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR: Magnesium.
CC   -!- INTERACTION:
CC       Self; NbExp=1; IntAct=EBI-447690, EBI-447690;
CC       P51617:IRAK1; NbExp=1; IntAct=EBI-447690, EBI-358664;
CC       O43187:IRAK2; NbExp=1; IntAct=EBI-447690, EBI-447733;
CC       Q99836:MYD88; NbExp=1; IntAct=EBI-447690, EBI-447677;
CC       Q9Y4K3:TRAF6; NbExp=1; IntAct=EBI-447690, EBI-359276;
CC   -!- TISSUE SPECIFICITY: Expressed predominantly in peripheral blood
CC       lymphocytes.
CC   -!- DISEASE: Defects in IRAK3 are associated with susceptibility to
CC       asthma-related traits type 5 (ASRT5) [MIM:611064]. Asthma-related
CC       traits include clinical symptoms of asthma, such as coughing,
CC       wheezing, dyspnea, bronchial hyperresponsiveness as assessed by
CC       methacholine challenge test, serum IgE levels, atopy, and atopic
CC       dermatitis.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. Pelle subfamily.
CC   -!- SIMILARITY: Contains 1 death domain.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- CAUTION: Ser-293 is present instead of the conserved Asp which is
CC       expected to be an active site residue. Low level
CC       autophosphorylation activity has been reported in PubMed:10383454,
CC       while other authors describe this as an inactive kinase.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF113136; AAD40879.1; -; mRNA.
DR   EMBL; BC057800; AAH57800.1; -; mRNA.
DR   EMBL; BC069388; AAH69388.1; -; mRNA.
DR   IPI; IPI00026984; -.
DR   RefSeq; NP_009130.2; -.
DR   UniGene; Hs.369265; -.
DR   ProteinModelPortal; Q9Y616; -.
DR   SMR; Q9Y616; 2-106, 151-445.
DR   IntAct; Q9Y616; 7.
DR   MINT; MINT-97148; -.
DR   STRING; Q9Y616; -.
DR   PhosphoSite; Q9Y616; -.
DR   PRIDE; Q9Y616; -.
DR   Ensembl; ENST00000261233; ENSP00000261233; ENSG00000090376.
DR   GeneID; 11213; -.
DR   UCSC; uc001sth.1; human.
DR   CTD; 11213; -.
DR   GeneCards; GC12P066582; -.
DR   H-InvDB; HIX0036700; -.
DR   HGNC; HGNC:17020; IRAK3.
DR   MIM; 604459; gene.
DR   MIM; 611064; phenotype.
DR   PharmGKB; PA38431; -.
DR   eggNOG; prNOG12619; -.
DR   HOGENOM; HBG446268; -.
DR   HOVERGEN; HBG052146; -.
DR   InParanoid; Q9Y616; -.
DR   BRENDA; 2.7.11.1; 247.
DR   Pathway_Interaction_DB; il1pathway; IL1-mediated signaling events.
DR   NextBio; 42675; -.
DR   ArrayExpress; Q9Y616; -.
DR   Bgee; Q9Y616; -.
DR   CleanEx; HS_IRAK3; -.
DR   Genevestigator; Q9Y616; -.
DR   GermOnline; ENSG00000090376; Homo sapiens.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0070498; P:interleukin-1-mediated signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0002755; P:MyD88-dependent toll-like receptor signalin...; TAS:BHF-UCL.
DR   GO; GO:0001960; P:negative regulation of cytokine-mediated si...; IC:BHF-UCL.
DR   GO; GO:0045824; P:negative regulation of innate immune response; ISS:BHF-UCL.
DR   GO; GO:0032695; P:negative regulation of interleukin-12 produ...; IMP:BHF-UCL.
DR   GO; GO:0032715; P:negative regulation of interleukin-6 produc...; IMP:BHF-UCL.
DR   GO; GO:0010936; P:negative regulation of macrophage cytokine ...; ISS:BHF-UCL.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; IMP:BHF-UCL.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcript...; IMP:BHF-UCL.
DR   GO; GO:0042177; P:negative regulation of protein catabolic pr...; IMP:BHF-UCL.
DR   GO; GO:0043242; P:negative regulation of protein complex disa...; IMP:BHF-UCL.
DR   GO; GO:0034122; P:negative regulation of toll-like receptor s...; ISS:BHF-UCL.
DR   GO; GO:0032720; P:negative regulation of tumor necrosis facto...; IMP:BHF-UCL.
DR   GO; GO:0010933; P:positive regulation of macrophage tolerance...; ISS:BHF-UCL.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcript...; IMP:BHF-UCL.
DR   GO; GO:0043330; P:response to exogenous dsRNA; ISS:BHF-UCL.
DR   GO; GO:0070555; P:response to interleukin-1; IMP:BHF-UCL.
DR   GO; GO:0032496; P:response to lipopolysaccharide; ISS:BHF-UCL.
DR   GO; GO:0032494; P:response to peptidoglycan; ISS:BHF-UCL.
DR   GO; GO:0009615; P:response to virus; IC:BHF-UCL.
DR   InterPro; IPR000488; Death.
DR   InterPro; IPR011029; DEATH-like.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   Gene3D; G3DSA:1.10.533.10; DEATH_like; 1.
DR   Pfam; PF00531; Death; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00005; DEATH; 1.
DR   SUPFAM; SSF47986; DEATH_like; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS50017; DEATH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; FALSE_NEG.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; FALSE_NEG.
PE   1: Evidence at protein level;
KW   ATP-binding; Complete proteome; Kinase; Magnesium; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Serine/threonine-protein kinase;
KW   Transferase.
FT   CHAIN         1    596       Interleukin-1 receptor-associated kinase
FT                                3.
FT                                /FTId=PRO_0000086033.
FT   DOMAIN       41    106       Death.
FT   DOMAIN      165    452       Protein kinase.
FT   NP_BIND     171    179       ATP (By similarity).
FT   BINDING     192    192       ATP (By similarity).
FT   MOD_RES     110    110       Phosphoserine.
FT   MOD_RES     154    154       Phosphoserine.
FT   MOD_RES     415    415       Phosphoserine.
FT   MOD_RES     467    467       Phosphoserine.
FT   MOD_RES     484    484       Phosphoserine.
FT   MOD_RES     510    510       Phosphoserine.
FT   MOD_RES     512    512       Phosphoserine.
FT   VARIANT      22     22       P -> L (may be associated with ASRT5).
FT                                /FTId=VAR_035212.
FT   VARIANT      57     57       H -> R (in dbSNP:rs35239505).
FT                                /FTId=VAR_040581.
FT   VARIANT      84     84       G -> S (in dbSNP:rs34443407).
FT                                /FTId=VAR_040582.
FT   VARIANT     111    111       P -> A (may be associated with ASRT5).
FT                                /FTId=VAR_035213.
FT   VARIANT     134    134       V -> M (may be associated with ASRT5).
FT                                /FTId=VAR_035214.
FT   VARIANT     147    147       V -> I (in dbSNP:rs1152888).
FT                                /FTId=VAR_019812.
FT   VARIANT     171    171       I -> V (in dbSNP:rs34682166).
FT                                /FTId=VAR_040583.
FT   VARIANT     269    269       G -> S (in dbSNP:rs35823766).
FT                                /FTId=VAR_033901.
FT   VARIANT     270    270       I -> V (in dbSNP:rs11465972).
FT                                /FTId=VAR_031077.
FT   VARIANT     288    288       S -> L (in dbSNP:rs35574245).
FT                                /FTId=VAR_040584.
FT   VARIANT     384    384       R -> Q (in dbSNP:rs34272472).
FT                                /FTId=VAR_040585.
FT   VARIANT     391    391       M -> T (in dbSNP:rs35737689).
FT                                /FTId=VAR_040586.
FT   VARIANT     400    400       L -> V (may be associated with ASRT5).
FT                                /FTId=VAR_035215.
FT   VARIANT     429    429       R -> Q (may be associated with ASRT5).
FT                                /FTId=VAR_035216.
FT   VARIANT     482    482       D -> N (in dbSNP:rs35756811).
FT                                /FTId=VAR_040587.
SQ   SEQUENCE   596 AA;  67753 MW;  E37433EADD7E38BE CRC64;
     MAGNCGARGA LSAHTLLFDL PPALLGELCA VLDSCDGALG WRGLAERLSS SWLDVRHIEK
     YVDQGKSGTR ELLWSWAQKN KTIGDLLQVL QEMGHRRAIH LITNYGAVLS PSEKSYQEGG
     FPNILFKETA NVTVDNVLIP EHNEKGVLLK SSISFQNIIE GTRNFHKDFL IGEGEIFEVY
     RVEIQNLTYA VKLFKQEKKM QCKKHWKRFL SELEVLLLFH HPNILELAAY FTETEKFCLI
     YPYMRNGTLF DRLQCVGDTA PLPWHIRIGI LIGISKAIHY LHNVQPCSVI CGSISSANIL
     LDDQFQPKLT DFAMAHFRSH LEHQSCTINM TSSSSKHLWY MPEEYIRQGK LSIKTDVYSF
     GIVIMEVLTG CRVVLDDPKH IQLRDLLREL MEKRGLDSCL SFLDKKVPPC PRNFSAKLFC
     LAGRCAATRA KLRPSMDEVL NTLESTQASL YFAEDPPTSL KSFRCPSPLF LENVPSIPVE
     DDESQNNNLL PSDEGLRIDR MTQKTPFECS QSEVMFLSLD KKPESKRNEE ACNMPSSSCE
     ESWFPKYIVP SQDLRPYKVN IDPSSEAPGH SCRSRPVESS CSSKFSWDEY EQYKKE
//
